{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:06:20Z","timestamp":1784819180914,"version":"3.55.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, effective as treatment for advanced non-small cell lung cancer; however, no quality evidence of its benefit in leptomeningeal carcinomatosis has been reported. Previous case series suggest that higher doses are more effective, if higher concentrations reach the central nervous system. Here, we present the case of a 42-year-old Chilean patient with\n                    <jats:italic>EGFR<\/jats:italic>\n                    -mutant lung cancer and leptomeningeal metastasis. A multimodal treatment was performed with intrathecal chemotherapy, craniospinal radiotherapy and erlotinib (150 mg\/day) for 5 years. At the time of this publication, she remained disease-free, and no\n                    <jats:italic>EGFR<\/jats:italic>\n                    mutation was detected via liquid biopsy. Further investigation is needed to determine the optimal anti EGFR regimen, the intrathecal chemotherapy protocol, and their sequencing. It is also of particular interest to identify factors associated with disease progression, and which are predictors of a good response to tyrosine kinase inhibitor among such patients.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1739717","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:25:33Z","timestamp":1778732733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis"],"prefix":"10.3389","volume":"16","author":[{"given":"Diego","family":"Neira","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednico Universidad de Chile","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital San Juan de Dios","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Nu\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednico Universidad de Chile","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Navarrete","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednico Universidad de Chile","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Vasquez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednico Universidad de Chile","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednico Universidad de Chile","place":["Santiago, Chile"]},{"name":"Departments of Medicine and Basic and Clinical Oncology and Center for Cancer Prevention and Control (CECAN), Faculty of Medicine, Universidad de Chile","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Barajas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednico Universidad de Chile","place":["Santiago, Chile"]},{"name":"Departments of Medicine and Basic and Clinical Oncology and Center for Cancer Prevention and Control (CECAN), Faculty of Medicine, Universidad de Chile","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.1999.0119","article-title":"Leptomeningeal carcinomatosis","volume":"25","author":"Grossman","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.04.013","article-title":"Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature","volume":"77","author":"Togashi","year":"2012","journal-title":"Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.10.016","article-title":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI","volume":"65","author":"Yi","year":"2009","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0963","article-title":"Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib","volume":"27","author":"Dhruva","year":"2009","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-010-0128-6","article-title":"High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer","volume":"99","author":"Clarke","year":"2010","journal-title":"J Neuro-Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor121","article-title":"Pulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu261","article-title":"Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better","volume":"25","author":"Cessot","year":"2014","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40262-013-0058-5","article-title":"Population pharmacokinetics\/ pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer","volume":"52","author":"Fukudo","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.07.003","article-title":"Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors","volume":"78","author":"Honda","year":"2012","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2021.11.064","article-title":"Spontaneous regression of an epidermal growth factor receptor-mutant left upper lobe adenocarcinoma","volume":"114","author":"Schiavon","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050940","article-title":"ctDNA for the evalution and management of egfr mutant non-small cell lung cancer","volume":"16","author":"Desai","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM Study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M- positive advanced NSCLC: The AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/PO.20.00464","article-title":"Standard-dose Osimertinib in EGFR-mutated non-small-cell lung adenocarcinoma with leptomeningeal disease","volume":"5","author":"McLean","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2024-2589","article-title":"FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases","volume":"14","author":"Sun","year":"2025","journal-title":"Transl Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1739717\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:25:57Z","timestamp":1778732757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1739717\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1739717"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1739717","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1739717"}}